MedTrace Logo

Impact of Sodium Glucose Co-transporter 2-Inhibitors on Clinical Outcome and Left Ventricular Function in Patients Presented by Acute Myocardial Infarction

NCT06964607 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2025-05-09

No results posted yet for this study

Summary

This study aimed to assess the effect of adding sodium glucose co-transporter two inhibitors on clinical outcome and left ventricular function in patients with acute myocardial Infarction.

Conditions

  • Sodium-glucose Cotransporter 2
  • Inhibitors
  • Clinical Outcome
  • Left Ventricule
  • Acute Myocardial Infarction

Interventions

DRUG

Sodium-glucose cotransporter-2 Inhibitors

Patients received conventional management of acute myocardial infarction and reperfusion therapy as indicated, plus one of the available sodium-glucose co-transporter-2 Inhibitors in Egypt (Empagliflozin or Dapagliflozin), irrespective of the presence or absence of diabetes mellitus or type of heart failure(HFrEF, HFmEF, HFpEF).

DRUG

Conventional treatment

Patients received conventional management of acute myocardial infarction and reperfusion therapy as indicated without adding sodium-glucose co-transporter-2 inhibitors.

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-01
Primary Completion
2024-04-01
Completion
2024-04-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06964607 on ClinicalTrials.gov